JP7402223B2 - 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用 - Google Patents

抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用 Download PDF

Info

Publication number
JP7402223B2
JP7402223B2 JP2021510030A JP2021510030A JP7402223B2 JP 7402223 B2 JP7402223 B2 JP 7402223B2 JP 2021510030 A JP2021510030 A JP 2021510030A JP 2021510030 A JP2021510030 A JP 2021510030A JP 7402223 B2 JP7402223 B2 JP 7402223B2
Authority
JP
Japan
Prior art keywords
antigen
amino acid
fcεr1α
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533806A5 (cg-RX-API-DMAC7.html
JP2021533806A (ja
Inventor
ジェイミー エム. オレンゴ,
アンドレ リムナンダー,
ジ エイチ. キム,
アンドリュー ジェイ. マーフィー,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021533806A publication Critical patent/JP2021533806A/ja
Publication of JP2021533806A5 publication Critical patent/JP2021533806A5/ja
Priority to JP2023172194A priority Critical patent/JP7541167B2/ja
Application granted granted Critical
Publication of JP7402223B2 publication Critical patent/JP7402223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021510030A 2018-08-23 2019-08-22 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用 Active JP7402223B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172194A JP7541167B2 (ja) 2018-08-23 2023-10-03 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721921P 2018-08-23 2018-08-23
US62/721,921 2018-08-23
PCT/US2019/047601 WO2020041537A1 (en) 2018-08-23 2019-08-22 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172194A Division JP7541167B2 (ja) 2018-08-23 2023-10-03 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用

Publications (3)

Publication Number Publication Date
JP2021533806A JP2021533806A (ja) 2021-12-09
JP2021533806A5 JP2021533806A5 (cg-RX-API-DMAC7.html) 2022-08-04
JP7402223B2 true JP7402223B2 (ja) 2023-12-20

Family

ID=67876086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510030A Active JP7402223B2 (ja) 2018-08-23 2019-08-22 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用
JP2023172194A Active JP7541167B2 (ja) 2018-08-23 2023-10-03 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172194A Active JP7541167B2 (ja) 2018-08-23 2023-10-03 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用

Country Status (18)

Country Link
US (2) US11578127B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840841A1 (cg-RX-API-DMAC7.html)
JP (2) JP7402223B2 (cg-RX-API-DMAC7.html)
KR (1) KR102977145B1 (cg-RX-API-DMAC7.html)
CN (1) CN112888482B (cg-RX-API-DMAC7.html)
AU (1) AU2019325565B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003023A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109513A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021000437A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003608A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190601A1 (cg-RX-API-DMAC7.html)
IL (1) IL280745B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002165A (cg-RX-API-DMAC7.html)
MY (1) MY204368A (cg-RX-API-DMAC7.html)
PH (1) PH12021550322A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101608XA (cg-RX-API-DMAC7.html)
WO (1) WO2020041537A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100919B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
US20230056380A1 (en) * 2020-01-31 2023-02-23 Randy Leiman Allen Methods and kit for detection of analytes
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515780A (ja) 2004-09-02 2008-05-15 ジェネンテック・インコーポレーテッド 抗FcγRIIBレセプター抗体およびその使用
WO2017180913A2 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018067331A1 (en) 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2012142286A1 (en) * 2011-04-12 2012-10-18 University Of Cincinnati Methods for suppressing allergic reactions
WO2012169741A2 (ko) 2011-06-07 2012-12-13 (주)네오팜 FcεRI 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN104293738A (zh) 2013-09-11 2015-01-21 李莉 一种抗人FcεRⅠα亚基单克隆抗体及其应用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
EA035269B1 (ru) 2014-08-13 2020-05-22 Зуппремоль Гмбх АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР
CN104800164B (zh) 2015-04-13 2017-11-07 上海市第一人民医院 一种雷公藤免疫纳米粒及用途
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515780A (ja) 2004-09-02 2008-05-15 ジェネンテック・インコーポレーテッド 抗FcγRIIBレセプター抗体およびその使用
WO2017180913A2 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018067331A1 (en) 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY,2010年,Vol.285, No.27,pp.20850-20859

Also Published As

Publication number Publication date
JP2023171909A (ja) 2023-12-05
EA202190601A1 (ru) 2021-07-14
IL280745B2 (en) 2026-06-01
KR102977145B1 (ko) 2026-06-12
US20230331845A1 (en) 2023-10-19
EP3840841A1 (en) 2021-06-30
IL280745A (en) 2021-04-29
PH12021550322A1 (en) 2021-10-04
US12441797B2 (en) 2025-10-14
US11578127B2 (en) 2023-02-14
WO2020041537A1 (en) 2020-02-27
KR20210049863A (ko) 2021-05-06
WO2020041537A8 (en) 2020-09-10
JP7541167B2 (ja) 2024-08-27
MY204368A (en) 2024-08-26
CA3109513A1 (en) 2020-02-27
BR112021003023A2 (pt) 2021-05-11
ZA202100919B (en) 2025-10-29
CL2021000437A1 (es) 2021-09-03
CL2023000442A1 (es) 2023-11-24
CO2021003608A2 (es) 2021-04-30
NZ772900A (en) 2025-05-02
US20200062844A1 (en) 2020-02-27
SG11202101608XA (en) 2021-03-30
AU2019325565A1 (en) 2021-03-11
AU2019325565B2 (en) 2025-09-04
CN112888482B (zh) 2024-06-25
IL280745B1 (en) 2026-02-01
CN112888482A (zh) 2021-06-01
MX2021002165A (es) 2021-07-16
JP2021533806A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7586974B2 (ja) 二重特異性抗bcma×抗cd3抗体およびそれらの使用
JP7436603B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP7271637B2 (ja) 抗psma抗体、psma及びcd3と結合する二重特異性抗原結合分子、ならびにその使用
JP6711883B2 (ja) Pd−1に対するヒト抗体
TWI688573B (zh) 抗cd-3抗體,結合至cd3及cd20的雙專一性抗原結合分子,及其用途
JP2019088311A (ja) 抗il−33抗体及びその使用
US20160024208A1 (en) Human antibodies to nav1.7
JP7541167B2 (ja) 抗fcイプシロン-r1アルファ(fcer1a)抗体、fcer1aおよびcd3に結合する二重特異性抗原結合分子、ならびにそれらの使用
KR20260026068A (ko) Cd40 x cd40 이중특이적 항원 결합 분자 및 이의 용도
CN104781280A (zh) 抗前动力蛋白受体(prokr)抗体及其使用
EA048275B1 (ru) АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FcER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FcER1A И CD3, И ИХ ПРИМЕНЕНИЕ
NZ710831B2 (en) Anti-il-33 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231208

R150 Certificate of patent or registration of utility model

Ref document number: 7402223

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150